Ascribe Bioscience is an Ithaca, NY-based agricultural technology company founded in 2017 out of research at the Boyce Thompson Institute at Cornell University. The company’s small-molecule platform taps compounds from the soil microbiome to create environmentally friendly crop-protection products that match the ease of use and cost profile of conventional chemicals. Its lead product, Phytalix, is positioned as a broad-spectrum “biofungicide without compromise,” offering sustainable disease control alongside practical on-farm performance. Ascribe plans to ramp manufacturing and begin early commercialization, targeting first regulatory approval in Brazil later this year with the United States and additional markets to follow. Proceeds from its recent financing will also advance further R&D on next-generation natural crop-protection solutions. While the company has not disclosed revenue or user metrics, investors cite “dramatic yield gains” in field trials as validation of its technology. Overall, Ascribe aims to provide farmers worldwide with highly effective, sustainable tools to improve crop resilience and yields.

Total raised

$15M

Funding rounds

2

Latest round

Series A

Latest activity

Oct 2025